Paclitaxel With Pertuzumab Plus Trastuzumab in MBC
Published Online: Wednesday, August 28, 2013
For High-Definition, ClickThe FDA approved pertuzumab in June 2012 to be used in combination with trastuzumab and docetaxel for untreated patients with HER2-positive metastatic breast cancer (MBC). This approval was based on findings from the phase III CLEOPATRA trial. However, following its approval, there was a push led by physicians at Memorial Sloan-Kettering Cancer Center (MSKCC) to allow the regimen to include paclitaxel instead of docetaxel, moderator Adam M. Brufsky, MD, PhD, states.
At MSKCC, paclitaxel as a monotherapy and in combinations is preferred to docetaxel for the treatment of patients with MBC, suggests Andrew D. Seidman, MD. As a result, the institution undertook a phase II trial examining the safety and efficacy of paclitaxel, pertuzumab, and trastuzumab, which found similar efficacy to the combination with docetaxel.
These efforts culminated in compendia approval and an endorsement from the NCCN guidelines for the combination of weekly paclitaxel with trastuzumab and pertuzumab. However, for patients who receive adjuvant paclitaxel and relapse after a year to a year-and-a-half, docetaxel remains the preferred treatment, Seidman adds.
While the utilization of this regimen is commonly agreed upon in the frontline treatment of HER2-positive patients, determining the optimal second- and third-lines of therapy remains complex. To address this concern, institutions and organizations are developing a set of guidelines specifically for HR and HER2-positive MBC.
In closing, Seidman mentions two trials that helped establish combination strategies for patients with HR- and HER2-positive MBC. The first trial was the TAnDEM trial, which showed that trastuzumab plus anastrozole was superior to anastrozole alone for postmenopausal women. A second trial, Seidman notes, demonstrated that combining letrozole and lapatinib significantly improves progression-free survival for patients with MBC, compared to letrozole alone.
View More From This Discussion
Sara Hurvitz, MDAssistant Professor & Director,
Hematology/Oncology Breast Cancer Program, UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California
Joyce A. O’Shaughnessy, MDCo-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Edith A. Perez, MDDeputy Director of the Mayo Clinic Cancer Center, Director of the Breast Cancer Translational Genomics Program and the Breast Program at Mayo Clinic,
Hope S. Rugo, MDProfessor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California
Andrew D. Seidman, MDProfessor of Medicine, Weill Cornell Cancer Center, Attending Physician at Memorial Sloan Kettering Cancer Center,
New York, New York
Online CME Activities
Most Popular Right Now
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.